Gilead新HBV Pipeline

瑞雪丰年

Hepatitis B Pipeline

In addition, Gilead has several ongoing research programs with the goal of achieving functional cure for HBV-infected patients. Preclinical data with some of Gilead’s novel investigational compounds are being presented at the Congress.

GS-5801 is an oral liver-targeted prodrug of a small molecule inhibitor of KDM5, a histone lysine demethylase. Results from in vitro preclinical studies (#SAT-160) demonstrated activity of GS-5801 in HBV-infected primary human hepatocytes with significant declines in viral proteins and HBV RNA. In addition, in vivo data (#THU-171) demonstrated the pharmacodynamic response of GS-5801 within the liver, in animal models. GS-5801 is currently being evaluated in Phase 1 trials in healthy subjects and in patients with chronic HBV infection.

GS-9688, an oral selective toll-like receptor 8 (TLR8) agonist, demonstrated in vitro and in vivo pharmacodynamic effects consistent with selective TLR8 activation, including the production of antiviral cytokines (#SAT-168). Further, in an efficacy animal model of chronic HBV infection, GS-9688 treatment demonstrated a sustained antiviral response in chronically infected woodchucks (#SAT-165). GS-9688 is currently being evaluated in Phase 1 trials in healthy subjects and in patients with chronic HBV infection.

Further information about the clinical studies described above can be found at http://anzctr.org.au/.

GS-5801 and GS-9688 are investigational products and have not been determined to be safe or efficacious.

瑞雪丰年

回复 瑞雪丰年 的帖子

乙型肝炎管道

此外，吉利德还有几个正在进行的研究计划，旨在实现HBV感染患者的功能治疗。大会上正在提交与吉列德一些新型研究化合物有关的临床前资料。

GS-5801是KDM5的小分子抑制剂 - 组蛋白赖氨酸脱甲基酶的口服肝靶向前药。来自体外临床前研究（＃SAT-160）的结果表明GS-5801在HBV感染的原代人肝细胞中的活性，病毒蛋白和HBV RNA显着下降。另外，在动物模型中，体内数据（＃THU-171）证实了GS-5801在肝脏内的药效学反应。 GS-5801目前正在健康受试者和慢性HBV感染患者的1期试验中进行评估。

口服选择性收费样受体8（TLR8）激动剂的GS-9688证明与选择性TLR8活化（包括抗病毒细胞因子的产生）（＃SAT-168）一致的体外和体内药效学效应。此外，在慢性HBV感染的功效动物模型中，GS-9688治疗在长期感染的土拨鼠（＃SAT-165）中表现出持续的抗病毒反应。 GS-9688目前正在健康受试者和慢性HBV感染患者的1期试验中进行评估。

有关上述临床研究的更多信息，请访问http://anzctr.org.au/。

GS-5801和GS-9688是研究产品，尚未确定为安全或有效。

kite2002005

人工智能如果能用来开发新药，会有多快

灵魂不屈

回复 kite2002005 的帖子

也许未来人工智能真的会用来开发新药！